Source: International Congress 2019 – Therapeutic breakthrough Year in review
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Cazzola (Roma (RM), Italy). Triple therapy versus dual bronchodilation and long-acting ß-agonists/inhaled corticosteroids in COPD: accumulating evidence from network meta-analyses. International Congress 2019 – Therapeutic breakthrough Year in review

Member's Comments

No comment yet.

Related content which might interest you: Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis Source: Eur Respir J, 52 (6) 1801586; 10.1183/13993003.01586-2018 Year: 2018 First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007 Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control Year: 2007 Treatment with inhaled corticosteroids (ICS) and long acting b2-agonists (LABA) combination in patients with COPD: Possible way of optimization Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011 Triple combination of montelukast or tiotropium and inhaled corticosteroids plus long-acting ß2-agonist in persistent asthma Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018 A systematic review and meta-analysis of the effect of dual versus mono- long-acting bronchodilator therapy on exercise endurance in COPD Source: International Congress 2016 – Latest insights into functional capacity and muscle weakness in chronic lung diseases Year: 2016 The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments Source: International Congress 2015 – New insights into exercise and muscle performance Year: 2015 Emerging inhaled bronchodilators: an update Source: Eur Respir J 2009; 34: 757 Year: 2009 Inhaled corticosteroids in COPD: the clinical evidence Source: Eur Respir J 2015; 45: 525-537 Year: 2015 Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Inhaled corticosteroid combined with long-acting bronchodilator versus long-acting bronchodilator alone for older patients with COPD Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015 The IMPACT of triple versus dual single-inhaler therapy on exacerbations of COPD Source: Breathe, 14 (4) 333; 10.1183/20734735.026418 Year: 2018 The impact of tiotropium on mortality when added to inhaled corticosteroids and long-acting beta agonist therapy in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 Once- vs. twice-daily inhaled therapy in asthma: a network meta-analysis Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019 Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004 Inhaled corticosteroids: a controversial add-on treatment in COPD Source: Eur Respir J 2010; 36: 973-974 Year: 2010 The effect of combined β2-agonist and anticholinergic inhaled therapy in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004